Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018231589) METHOD FOR DETERMINING LYMPHOMA TYPE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIM(S):

1. A method for classifying the lymphoma type of a sample, the method comprising:

(a) providing a formalin-fixed and paraffin-embedded (FFPE) lymphoma sample from the subject;

(b) isolating RNA from the sample;

(c) obtaining gene expression data from the RNA,

wherein the gene expression data comprises signal values that represent expression levels for each gene of Table 1; and

(d) determining a tumor predictor score from the gene expression data, wherein the tumor predictor score is calculated by


wherein αi is the model coefficient value for gene i as listed in Table 1, column D for determining whether the sample is PMBCL or DLBCL and as listed in Table 1, column E for determining whether the sample is ABC DLBCL or GCB DLBCL,

and Xi is the log2 transformed expression signal value for gene i; and

(e) when the coefficient values in column D of Table 1 are used, classifying the lymphoma as:

(i) DLBCL when S is less than -57.95,

(ii) PMBCL when S is greater than -23.57,

(iii) uncertain DLBCL/PMBCL when S is between -57.95 and -23.57,

(e') when the coefficient values in column E of Table 1 are used, classifying the lymphoma as:

(iv) GCB DLBCL when S is less than 798.5,

(v) ABC DLBCL when S is greater than 1324.5, or

(vi) uncertain ABC/GCB DLBCL when S is between 798.5 and 1324.5.

2. The method of claim 1 , wherein the method further comprises determining the probability that the sample is PMBCL or ABC DLBCL, wherein the probability is determined by

(h) determining the probability that the sample is PMBCL by calculating the

probability score of


wherein is the tumor predictor score;



represent the mean and standard deviations of the PMBL and DLBCL subtypes as indicated in Table 2;

(h) determining the probability that the samples is ABC DLBCL by calculating the probability score of


wherein S is the tumor predictor score; and represent the mean and standard deviations of the ABC and GCB subtypes as indicated in Table 2; and

wherein φ(χ; μ, σ) is the standard normal density calculated by


3. The method of claim 2, wherein a score of P(PMBCL) > 0.9 indicates that the sample is PMBCL, regardless of the P(ABC) score.

4. The method of claim 2, wherein a score of P(PMBCL) < 0.1 and a score of P(ABC) < 0.1 indicates that the tumor is GCB DLBCL.

5. The method of claim 2, wherein a score of P(PMBCL) < 0.1 and a score of P(ABC) > 0.9 indicates that the tumor is ABC DLBCL.

6. The method of claim 2, wherein a score of P(PMBCL) < 0.1 and a score of P(ABC) greater than 0.1 and less than 0.9 indicates that the tumor is an unclassified DLBCL.

7. The method of any one of claims 1-6, wherein the RNA gene expression data is obtained using a NanoString Technologies® nCounter® assay.